Cargando…

Real-word adrenocorticotropic hormone treatment for childhood-onset nephrotic syndrome

BACKGROUND: Current first-line anti-proteinuric treatments do not produce a satisfactory therapeutic effect in a considerable number of patients with nephrotic syndrome (NS). Interest in adrenocorticotropic hormone (ACTH) for the treatment of NS has recently been revived. The present study investiga...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ying, Dang, Xiqiang, Wu, Xiaochuan, Li, Yongzhen, He, Qingnan, Li, Xiaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036038/
https://www.ncbi.nlm.nih.gov/pubmed/36969288
http://dx.doi.org/10.3389/fped.2023.1044075
_version_ 1784911554468118528
author Wang, Ying
Dang, Xiqiang
Wu, Xiaochuan
Li, Yongzhen
He, Qingnan
Li, Xiaoyan
author_facet Wang, Ying
Dang, Xiqiang
Wu, Xiaochuan
Li, Yongzhen
He, Qingnan
Li, Xiaoyan
author_sort Wang, Ying
collection PubMed
description BACKGROUND: Current first-line anti-proteinuric treatments do not produce a satisfactory therapeutic effect in a considerable number of patients with nephrotic syndrome (NS). Interest in adrenocorticotropic hormone (ACTH) for the treatment of NS has recently been revived. The present study investigated the efficacy and safety of ACTH treatment in children with frequent relapsing NS (FRNS), steroid-dependent NS (SDNS), and steroid-resistant NS (SRNS). METHOD: The ACTH treatment group was comprised of NS patients receiving ACTH treatment. Patients with serum cortisol concentrations <85.3 nmol/L and who had not received ACTH treatment previously were enrolled in the control group from January 2018 to January 2021. The maintenance dose of prednisone, the number of disease recurrences, the time of first disease relapse, immunosuppressant use, serum cortisol levels, and adverse events were recorded in both groups. RESULTS: Fifty-one patients were included in the ACTH group, and twenty-one patients were enrolled in the control group. Concurrent treatment with one or more immunosuppressive and/or cytotoxic treatments occurred in 92.2% and 85.7% of patients in the ACTH and control groups, respectively, throughout the study period. A greater reduction in the prednisone maintenance dose was observed in the ACTH group compared with the control group after 1 year of follow up (0.603 ± 0.445 mg/kg vs. 0.267 ± 0.500 mg/kg, p = 0.006). During the one-year study period, fewer participants experienced one or more disease relapses in the ACTH group (45.1%) compared to the control group (76.2%, odds ratio = 3.896, p = 0.016). The number of disease recurrences per patient in the ACTH group was less than that in the control group (median difference = −1, p = 0.006). The mean length of remission was 8.902 m and 7.905 m in the ACTH group and control group, respectively. A log-rank test showed a longer relapse free survival for patients in the ACTH group (p = 0.046), but the Breslow test showed no significant difference between groups (p = 0.104). Ten patients in the ACTH group successfully discontinued all drug therapies. No patients in the control group were able to discontinue drug therapy as of February 2022. CONCLUSION: ACTH, combined with multiple drugs, is effective at reducing the prednisone maintenance dose and may effectively prevent disease relapses in childhood NS.
format Online
Article
Text
id pubmed-10036038
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100360382023-03-24 Real-word adrenocorticotropic hormone treatment for childhood-onset nephrotic syndrome Wang, Ying Dang, Xiqiang Wu, Xiaochuan Li, Yongzhen He, Qingnan Li, Xiaoyan Front Pediatr Pediatrics BACKGROUND: Current first-line anti-proteinuric treatments do not produce a satisfactory therapeutic effect in a considerable number of patients with nephrotic syndrome (NS). Interest in adrenocorticotropic hormone (ACTH) for the treatment of NS has recently been revived. The present study investigated the efficacy and safety of ACTH treatment in children with frequent relapsing NS (FRNS), steroid-dependent NS (SDNS), and steroid-resistant NS (SRNS). METHOD: The ACTH treatment group was comprised of NS patients receiving ACTH treatment. Patients with serum cortisol concentrations <85.3 nmol/L and who had not received ACTH treatment previously were enrolled in the control group from January 2018 to January 2021. The maintenance dose of prednisone, the number of disease recurrences, the time of first disease relapse, immunosuppressant use, serum cortisol levels, and adverse events were recorded in both groups. RESULTS: Fifty-one patients were included in the ACTH group, and twenty-one patients were enrolled in the control group. Concurrent treatment with one or more immunosuppressive and/or cytotoxic treatments occurred in 92.2% and 85.7% of patients in the ACTH and control groups, respectively, throughout the study period. A greater reduction in the prednisone maintenance dose was observed in the ACTH group compared with the control group after 1 year of follow up (0.603 ± 0.445 mg/kg vs. 0.267 ± 0.500 mg/kg, p = 0.006). During the one-year study period, fewer participants experienced one or more disease relapses in the ACTH group (45.1%) compared to the control group (76.2%, odds ratio = 3.896, p = 0.016). The number of disease recurrences per patient in the ACTH group was less than that in the control group (median difference = −1, p = 0.006). The mean length of remission was 8.902 m and 7.905 m in the ACTH group and control group, respectively. A log-rank test showed a longer relapse free survival for patients in the ACTH group (p = 0.046), but the Breslow test showed no significant difference between groups (p = 0.104). Ten patients in the ACTH group successfully discontinued all drug therapies. No patients in the control group were able to discontinue drug therapy as of February 2022. CONCLUSION: ACTH, combined with multiple drugs, is effective at reducing the prednisone maintenance dose and may effectively prevent disease relapses in childhood NS. Frontiers Media S.A. 2023-03-09 /pmc/articles/PMC10036038/ /pubmed/36969288 http://dx.doi.org/10.3389/fped.2023.1044075 Text en © 2023 Wang, Dang, Wu, Li, He and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Wang, Ying
Dang, Xiqiang
Wu, Xiaochuan
Li, Yongzhen
He, Qingnan
Li, Xiaoyan
Real-word adrenocorticotropic hormone treatment for childhood-onset nephrotic syndrome
title Real-word adrenocorticotropic hormone treatment for childhood-onset nephrotic syndrome
title_full Real-word adrenocorticotropic hormone treatment for childhood-onset nephrotic syndrome
title_fullStr Real-word adrenocorticotropic hormone treatment for childhood-onset nephrotic syndrome
title_full_unstemmed Real-word adrenocorticotropic hormone treatment for childhood-onset nephrotic syndrome
title_short Real-word adrenocorticotropic hormone treatment for childhood-onset nephrotic syndrome
title_sort real-word adrenocorticotropic hormone treatment for childhood-onset nephrotic syndrome
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036038/
https://www.ncbi.nlm.nih.gov/pubmed/36969288
http://dx.doi.org/10.3389/fped.2023.1044075
work_keys_str_mv AT wangying realwordadrenocorticotropichormonetreatmentforchildhoodonsetnephroticsyndrome
AT dangxiqiang realwordadrenocorticotropichormonetreatmentforchildhoodonsetnephroticsyndrome
AT wuxiaochuan realwordadrenocorticotropichormonetreatmentforchildhoodonsetnephroticsyndrome
AT liyongzhen realwordadrenocorticotropichormonetreatmentforchildhoodonsetnephroticsyndrome
AT heqingnan realwordadrenocorticotropichormonetreatmentforchildhoodonsetnephroticsyndrome
AT lixiaoyan realwordadrenocorticotropichormonetreatmentforchildhoodonsetnephroticsyndrome